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ORIGINAL ARTICLEDrug resistance and genetic characteristics of clinical isolates of
staphylococci in Myanmar: high prevalence of PVL among methicillin-
susceptible Staphylococcus aureus belonging to various sequence typesM. S. Aung1, H. Zi2, K. M. Nwe3, W. W. Maw2, M. T. Aung4, W. W. Min5, N. Nyein6, M. Kawaguchiya1, N. Urushibara1,
A. Sumi1 and N. Kobayashi1
1) Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan, 2) Department of Microbiology, University of Medicine 2,
Yangon, 3) National Health Laboratory, Yangon, 4) Pathology Department, Microbiology Section, North Okkalapa General Hospital, Yangon, 5) Department of
Microbiology, University of Medicine Magway, Magway and 6) Department of Microbiology, University of Medicine, Mandalay, MyanmarAbstractPrevalence, drug resistance and genetic characteristics were analysed for a total of 128 clinical isolates of staphylococci obtained from a
tertiary hospital in Myanmar. The dominant species were S. aureus (39%) and S. haemolyticus (35%), followed by S. epidermidis (6%) and
S. saprophyticus (5%). The majority of S. haemolyticus isolates (71.1%) harboured mecA, showing high resistance rates to ampicillin,
cephalosporins, erythromycin and levoﬂoxacin, while methicillin-resistant S. aureus (MRSA) was only 8% (four isolates) among S. aureus
with type IV SCCmec. Panton-Valentine leukocidin (PVL) genes were detected in 20 isolates of S. aureus (40%), among which only one
isolate was MRSA belonging to sequence type (ST) 88/agr-III/coa-IIIa, and the other 19 methicillin-susceptible S. aureus (MSSA) isolates
were classiﬁed into six STs (ST88, ST121, ST1153, ST1155, ST1930, ST3206). An ST1153 MSSA isolate with PVL was revealed to belong
to a novel coa type, XIIIa. ST121 S. aureus was the most common in the PVL-positive MSSA (47%, 9/19), harbouring genes of bone
sialoprotein and variant of elastin binding protein as a distinctive feature. Although PVL-positive MSSA was susceptible to most of the
antimicrobial agents examined, ST1930 isolates were resistant to erythromycin and levoﬂoxacin. ST59 PVL-negative MRSA and MSSA had
more resistance genes than other MRSA and PVL-positive MSSA, showing resistance to more antimicrobial agents. This study indicated
higher prevalence of mecA associated with multiple drug resistance in S. haemolyticus than in S. aureus, and dissemination of PVL genes to
multiple clones of MSSA, with ST121 being dominant, among hospital isolates in Myanmar.
New Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: nkobayas@sapmed.ac.jpIntroductionStaphylococci constitute one of the major normal ﬂora in skin,
nasal cavities and mucosal membranes of humans. However,
they are known as common causes of various infections in bothw Microbe and New Infect 2016; 10: 58–65
w Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2015.12.007healthcare and community settings. While approximately 30%
of healthy individuals are colonized with Staphylococcus aureus
asymptomatically [1], this bacterium causes various infections,
including skin and soft tissue infections (SSTI), bactaeremia and
pneumonia. Healthcare-associated (HA) methicillin-resistant
Staphylococcus aureus (MRSA) has been recognized as a pri-
mary cause of nosocomial infections that acquired multiple drug
resistance, associated with its global spread since the 1960s [2].
Thereafter, community-acquired (CA) MRSA have also
emerged as cause of infections in individuals who have no
healthcare-associated risk [3,4], posing a public health concern
worldwide. Coagulase-negative staphylococci (CNS),European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
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nosocomial pathogens mainly as a result of development of
prosthetic devices and invasive medical technologies [5].
Representative species causing infections are S. epidermidis and
S. haemolyticus, which often acquire drug resistance, including
methicillin resistance via same genetic mechanism as that of
MRSA.
Methicillin resistance of staphylococcus is characterized by
the presence of a transmissible genome element, staphylococcal
cassette chromosome mec (SCCmec), which is inserted in the
chromosome of bacterial cell. SCCmec in MRSA has been
differentiated into at least 11 genetic types (I–XI) [6,7], among
which types I to III are commonly found in HA-MRSA, while
type IV and V were reported to be frequently in CA-MRSA [3].
However, in the present circumstances, CA-MRSA with the
dominant SCCmec types have been brought to healthcare
settings [8–10], which makes distinction between HA- and CA-
MRSA more difﬁcult in terms of SCCmec type. The initially
identiﬁed CA-MRSA strains were characterized by production
of Panton-Valentine leukocidin (PVL), a two-component leu-
kolytic toxin [11], which is associated with severe symptoms in
a wide spectrum of infections [12,13], including SSTI and
necrotizing pneumonia. Prevalence of CA-MRSA harbouring
PVL genes has been increasing recently in hospitalized patients
as well as healthy individuals in the community [14,15].
In Myanmar, S. aureus has been reported to be the major
pathogen in bloodstream infections and the third most common
bacteria in blood cultures from febrile children [16,17]. How-
ever, to our knowledge, there is no epidemiologic study on
staphylococci from healthcare settings in Myanmar, and thus
information is not available for drug resistance and genetic
characteristics on recent clinical isolates of S. aureus, including
MRSA, and CNS. Although we previously reported genetic
traits of MRSA and methicillin-susceptible S. aureus (MSSA)
isolates from hospital, community and food poisoning cases in
Myanmar, the epidemiologic features was not determined
because of the low numbers of isolates analysed [18]. In the
present study, drug resistance and genetic traits, including
prevalence of mecA, ACME (arginine catabolic mobile element)
and PVL genes, was analysed for clinical isolates of staphylococci
in a tertiary-care hospital in Myanmar.Materials and methodsBacterial isolates and initial genetic analysis
A total of 128 Staphylococcus strains were collected from pa-
tients admitted to North Okkalapa General Hospital, Yangon,
Myanmar, between January 2012 and August 2013. The main
specimen of the isolates was wound swab of surgical siteNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access artiinfections (57%), followed by high vaginal swab (12%), blood
(11%), pus (10%) and other specimens (sputum, urine, ear
exudate) (10%). A single isolate from an individual patient was
subjected to this study. Bacterial isolates grown on agar plates
were examined by conventional microbiologic methods, and
their species were determined by BBL Crystal Gram-Positive
ID Kit (Becton Dickinson Microbiology Systems, Cockeysville,
MD, USA). Individual bacterial strains were stored in Microbank
(Pro-Lab Diagnostics, Richmond Hill, ON, Canada) at −80°C
and recovered when they were analysed.
The presence of staphylococcal 16S rRNA, nuc, mecA, PVL
gene (lukS-PV/lukF-PV) and ACME-arcA (arginine deiminase gene)
were detected for all isolates by multiplex PCR assay as
described by Zhang et al. [19]. SCCmec type and ACME type
were also determined by multiplex PCR using previously pub-
lished primers and conditions [20,21].
Antimicrobial susceptibility testing
For major staphylococcal species, minimum inhibitory con-
centrations against 18 antimicrobial agents based on the broth
microdilution test were measured by using Dry Plate ‘Eiken’
DP32 (Eiken Chemical, Tokyo, Japan) for Gram-positive cocci.
Breakpoints deﬁned in the Clinical Laboratory Standards Insti-
tute (CLSI) guidelines were used to distinguish between resis-
tant and susceptible strains for most of the drugs examined
[22].
Genetic typing, detection of virulence factors and drug
resistance genes of S. aureus
The staphylocoagulase genotype (coa type) of S. aureus isolates
was determined by multiplex PCR using previously published
primers and conditions [23]. For the strains for which the coa
types were not determined for I–X by the multiplex PCR,
sequences of D1, D2 and the central region of coa were
determined as described previously [24,25] to assign the coa
genotype by sequence homology. Sequence identity to the
known coa types was analysed by Basic Local Alignment Search
Tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi). For
selected isolates, sequence type (ST) was determined according
to the scheme of multilocus sequence typing (MLST) [26], and
agr group classiﬁcation and protein A gene (spa) typing were
performed as described previously [27,28].
The presence of genes encoding enterotoxins and other
toxins, adhesins, other proteins related to virulence and anti-
microbial resistance genes were analysed by multiplex or uni-
plex PCR using primers described previously [18]. Partial
sequence of the gene encoding elastin-binding protein (ebpS)
was determined by PCR and direct sequencing as described
previously [18]. Multiple alignment of nucleotide and amino acid
sequences determined was performed by the CLUSTAL W 2.1f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 10, 58–65
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 2. Genotype (ST) of PVL-positive Staphylococcus
aureus isolates
mecA coa type ST CCa
No. of
isolates Specimen (n)
+ IIIa ST88 CC88 1 Wound (1)
60 New Microbes and New Infections, Volume 10 Number C, March 2016 NMNIprogram (DNA Data Bank of Japan (DDBJ), http://clustalw.ddbj.
nig.ac.jp/).
Full-length staphylocoagulase gene (coa) sequence of strain
MMR-v determined in the present study was deposited in the
GenBank database under accession number KT599478.− IIIa ST88 CC88 2 Blood (1), wound (1)
− Va ST121 CC121 9 Pus (2), wound (7)
− VIa ST1930 CC96 3 Pus (1), wound (2)
− VIa ST3206 CC1 2 Pus (1), wound (1)
− VIIa ST1155 CC101 2 Pus (1), high vaginal swab (1)Results
− XIIIa ST1153 CC1153 1 Wound (1)
CC, clonal complex; PVL, Panton-Valentine leukocidin; ST, sequence type.
aCC of ST.Among the 128 staphylococcal isolates obtained in the study
period, the dominant species identiﬁed were S. aureus (n = 50,
39%) and S. haemolyticus (n = 45, 35%), followed by
S. epidermidis (n = 8, 6%) and S. saprophyticus (n = 7, 5%).
S. aureus and S. haemolyticus were isolated from wound swabs at
high rates (65% and 62%, respectively), while S. haemolyticus
was the main species among isolates from blood culture (43%,
6/14). The majority of S. haemolyticus (71%, 32/45) and
S. epidermidis (75%, 6/8) possessed mecA, while the detection
rate of MRSA was only 8% (4/50), and all the four MRSA had
type IV SCCmec (Table 1). Although the SCCmec of some
S. haemolyticus and S. epidermidis isolates was assigned to types
IV and V, most of the isolates (71%, 27/38) were untypable.
ACME-arcA was detected in two and one isolates of
S. haemolyticus and S. epidermidis, respectively, and their ACME
was classiﬁed into type II. PVL genes were detected in
20 S. aureus isolates (40%), among which only one isolate was
MRSA. PVL-positive S. aureus were mostly isolated from pus or
wound swabs (Table 2).
While the four MRSA isolates showed resistance to oxacillin
and ampicillin, they were mostly susceptible to all other anti-
microbial agents, except for gentamicin and erythromycin
(Table 3). MSSA isolates were susceptible to most antimicrobial
agents while showing low resistance rates to ampicillin, eryth-
romycin, gentamicin and sulfamethoxazole/trimethoprim. In
contrast, mecA-positive S. haemolyticus showed high resistanceTABLE 1. Frequencies of isolates with PVL genes, ACME and mecA
Staphylococcus species mecA No. of isolates PVL genes (+)
S. aureus (n = 50) + 4 1
− 46 19
S. haemolyticus (n = 45) + 32 0
− 13 0
S. epidermidis (n = 8) + 6 0
− 2 0
S. saprophyticus (n = 7) + 1 0
− 6 0
Other (n = 18) + 3a 0
− 15c 0
PVL, Panton-Valentine leukocidin; NT, nontypeable.
aOne isolate each of S. hominis, S. sciuri and S. vitulinus.
bS. sciuri.
cS. auricularis (1), S. capitis (1), S. cohnii (1), S. hominis (1), S. kloosii (3), S. sciuri (1), S. vitulinus
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licerates to ampicillin, cephalosporins, erythromycin and levo-
ﬂoxacin. Similar to MRSA, mecA-positive S. epidermidis were
susceptible to most of the antimicrobial agents except for
oxacillin. None of the staphylococcal isolates was resistant to
vancomycin, linezolid and fosfomycin.
Among the 50 S. aureus isolates, ten staphylocoagulase (coa)
genotypes were identiﬁed by multiplex PCR or sequencing, and
the most common type was Va (n = 19), followed by VIIa
(n = 8), VIa (n = 6), and IIIa and VIIb (n = 4) (Table 4). Full-length
coa was determined for an MSSA strain MMR-v of which the coa
type was untypable by the PCR assay. Sequence identity of coa-
D1 region and -D2 plus central regions of MMR-v to the known
12 coa types were 64.7–70.3% and 69.7–89.2%, respectively
(Supplementary Table S1). According to the criteria to deter-
mine coa type (subtype) proposed by Watanabe et al. [25], i.e.
>90% identity of the D1 region (coa type) and >90% identity of
the D1 and central region (coa subtype), the staphylocoagulase
gene of MMR-v was considered not to be classiﬁed into the
known 12 coa types. Therefore, a new coa type, XIIIa, was
assigned to this strain. While MRSA belonged to three coa types
(IIIa, IVb, VIIb), PVL-positive isolates were assigned to ﬁve coa
types (IIIa, Va, VIa, VIIa, XIIIa), with Va being dominant, followed
by VIa.(SCCmec type) among different Staphylococcus species
ACME-arcA (+) (ACME type)
SCCmec type
II IV V NT
0 4
0
1 (ACMEII) 2 5 25
1 (ACMEII)






(1), S. warneri (3), S. xylosus (3).
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TABLE 3. Resistance rates of Staphylococcus species against antimicrobial agents
Antimicrobial
agenta
Resistant isolates, n (%)













OXA 4 (100) 0 (0) 29 (90.6) 4 (30.8) 6 (100) 1 (50)
FOX 1 (25) 0 (0) 28 (87.5) 2 (15.4) 0 (0) 2 (100)
AMP 4 (100) 15 (32.6) 28 (87.5) 1 (7.7) 1 (16.7) 0 (0)
CFZ 0 (0) 0 (0) 23 (71.9) 1 (7.7) 0 (0) 0 (0)
CMZ 0 (0) 0 (0) 17 (53.1) 1 (7.7) 0 (0) 1 (50)
FMX 0 (0) 0 (0) 7 (21.9) 2 (15.4) 0 (0) 1 (50)
IPM 0 (0) 0 (0) 14 (43.8) 0 (0) 0 (0) 0 (0)
GEN 2 (50) 6 (13) 25 (78.1) 0 (0) 1 (16.7) 1 (50)
ABK 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 1 (50)
MIN 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ERY 2 (50) 7 (15.2) 30 (93.8) 6 (46.2) 0 (0) 2 (100)
CLI 1 (25) 6 (13) 6 (18.8) 3 (23.1) 1 (16.7) 1 (50)
VAN 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
TEC 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
LZD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
FOF 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
LVX 1 (25) 3 (6.5) 28 (87.5) 1 (7.7) 3 (50) 1 (50)
STX 1 (25) 7 (15.2) 20 (62.5) 1 (7.7) 3 (50) 1 (50)
ABK, arbekacin; AMP, ampicillin; CFZ, cefazolin; CLI, clindamycin; CMZ, cefmetazole; ERY, erythromycin; FMX, ﬂomoxef; FOF, fosfomycin; FOX, cefoxitin; GEN, gentamicin; IPM,
imipenem; LVX, levoﬂoxacin; LZD, linezolid; MIN, minocycline; OXA, oxacillin; SXT, sulfamethoxazole/trimethoprim; TEC, teicoplanin; VAN, vancomycin.
aResistance to individual antimicrobial agents was judged according to Clinical Laboratory Standards Institute (CLSI) guidelines. For antimicrobial agents whose resistance is not
deﬁned by CLSI guidelines, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (Staphylococcus spp., FOF, >32 μg/mL) and the following deﬁnitions
(minimum inhibitory concentration) were used to determine resistance for S. aureus and S. haemolyticus: ABK, >4 μg/mL.
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7 PVL-negative S. aureus isolates, resulting in identiﬁcation of 11
STs (Tables 2 and 5). ST3206 (CC1) of two PVL-positive MSSA
isolates and ST3075 of a PVL-negative MSSA isolate were newly
identiﬁed in the present study. PVL-positive isolates were
differentiated into six STs (ST88, ST121, ST1153, ST1155,
ST1930, ST3206), among which ST121 was dominant (nine
isolates, 45% of PVL-positive S. aureus) and found in only MSSA,
and other STs were identiﬁed in one to three isolates. A PVL-
positive MRSA, strain MMR-42A, belonged to ST88, coa type
IIIa, agr type III, and spa type t729. The other three MRSA
isolates were classiﬁed into ST6 and ST59 (Table 5). ST88 was
also identiﬁed in PVL-positive MSSA from blood and wound,
which exhibited different patterns of toxin/virulence factors and
drug resistance from those of a PVL-positive ST88 MRSA.
ST121 PVL-positive MSSA isolates belonged to coa type Va andTABLE 4. Frequencies of PVL and mecA genes among
different coa genotype of Staphylococcus aureus isolates
coa type No. of isolates PVL(+) mecA(+)
IIa 2









Total 50 20 4
PVL, Panton-Valentine leukocidin.
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This is an open access artiagr type IV, and harboured ﬁve to six enterotoxin genes, the
bone sialoprotein gene (bbp), and a variant of the elastin binding
protein gene (ebpS-v) with an internal 180 bp deletion as
described previously [18]. The ST59 S. aureus, both MRSA (two
strains) and MSSA (one strain) without PVL had more resis-
tance genes (ermB, aac(60)-Ie-aph(200)-Ia) than other MRSA and
PVL-positive MSSA, showing resistance to more antimicrobial
agents.DiscussionIn the present study, prevalence and drug resistance of staph-
ylococcal species and genetic traits of S. aureus were elucidated
for clinical isolates in a tertiary hospital in Myanmar. Distinctive
features in this study were the high prevalence and antimicro-
bial resistance trend of S. haemolyticus, the low rate of MRSA,
and the high rate of PVL among MSSA.
Among CNS species, S. haemolyticus has been described as
occasionally the second most frequent clinical isolates after
S. epidermidis, causing primarily bloodstream infections associ-
ated with the use of central venous catheters [5]. In the present
study, with a lower number of blood isolates (11%), the fre-
quency of S. haemolyticus was comparable to S. aureus and higher
than that of S. epidermidis, suggesting the signiﬁcance of this
species in skin infections as well. In agreement with the view of
this species having a great capacity to develop resistance to
multiple classes of antimicrobial agents [29,30], a high mecA-
positive rate associated with high resistance rates to variousf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 10, 58–65
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 5. Genotypes, virulence factors and drug resistance in 15 MSSA and MRSA strains
mecA/









mec coa agr ST (CC)
PVL MMR-20A 34/M Blood IIIa III ST88 (CC88) lukE-lukD, hla, hlg2 seq sdrC, sdrD, sdrE, ﬁb, clfB, ebpS blaZ AMP
PVL MMR-k 36/F Wound Va IV ST121 (CC121) lukE-lukD, hla, hlg2 seb, sei, sem,
sen, seo
ﬁb, clfB, cna, bbp, ebpS-v blaZ AMP
PVL MMR-6A 30/M Pus Va IV ST121 (CC121) lukE-lukD, hla, hlg2 seb, seg, sei,
sem, sen, seo
ﬁb, clfB, cna, bbp, ebpS-v blaZ AMP
PVL MMR-z0 38/M Wound VIa III ST1930 (CC96) lukE-lukD, hla, hlg2 sea, sec, sei, sel sdrC, sdrD, sdrE, ﬁb, clfB, ebpS, cna blaZ, ermC AMP, ERY, LVX
PVL MMR-46A 49/M Wound VIa III ST1930 (CC96) lukE-lukD, hla, hlg2 sea, sec, sei, sel sdrC, sdrD, sdrE, ﬁb, clfB, ebpS blaZ, ermC AMP, ERY, LVX
PVL MMR-30B 30/F Pus VIIa I ST1155 (CC101) lukE-lukD, hla, hlg2 sdrC, sdrD, sdrE, ﬁb, clfB, ebpS, cna
PVL MMR-v 55/F Wound XIIIa II ST1153 (CC1153) lukE-lukD, hla, hlg2 sec, sei, sel sdrC, sdrD, sdrE, ﬁb, clfB, ebpS blaZ
− MMR-g 46/F Wound VIIa I ST2549 (CC45) hla sea, seg, sei,
sem, sen, seo
sdrC, sdrD, sdrE, clfB, ebpS, cna blaZ AMP, GEN
− MMR-44B 53/M Wound VIIc I ST59 (CC59) hla, hlg2 seb, sek, seq sdrC, sdrD, sdrE, ﬁb, clfB, ebpS blaZ, ermB, aac(60)-Ie-aph(200)-Ia, ant(6)-Ia AMP, GEN, ERY,
CLI, LVX
− MMR-a 43/M Wound VIIa I ST3075 (Singleton) hla, hlg2 sek sdrC, sdrD, sdrE, ﬁb, clfB, ebpS, cna blaZ, ant(40)-Ia, tet(K) AMP, GEN, MIN
− MMR-14B 20/M Blood Xa II ST2990 (Singleton) lukE-lukD, hlg2 sec, sel sdrC, sdrD, sdrE, ﬁb, ebpS, cna, edin-B blaZ AMP, ERY, CLI
mecA, PVL MMR-42A 56/M Wound IV IIIa III ST88 (CC88) lukE-lukD, hlg2 sei, sek, seq sdrC, sdrD, sdrE, ﬁb, clfB, ebpS blaZ, tetK OXA, AMP, MIN
mecA MMR-55B 25/F High
vaginal
swab
IV VIIb I ST59 (CC59) hla, hlg2 seb, sek, seq sdrC, sdrD, sdrE, ﬁb, clfB, ebpS blaZ, ermB, aac(60)-Ie-aph(200)-Ia OXA, AMP, GEN,
ERY, CLI, LVX
mecA MMR-57B 66/F Wound IV VIIb I ST59 (CC59) hla, hlg2 seb, sek, seq sdrC, sdrD, sdrE, ﬁb, ebpS blaZ, ermB, aac(60)-Ie-aph(200)-Ia OXA, FOX, AMP,
GEN, ERY, CLI,
LVX, SXT
mecA MMR-22B 20/F Wound IV IVb I ST6 (CC6) lukE-lukD, hla, hlg2 sea sdrC, sdrD, sdrE, ﬁb, ebpS, cna blaZ OXA, AMP
CC, clonal complex; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PVL, Panton-Valentine leukocidin; ST, sequence type.
aThe following genes were detected in all strains: clfA, eno, fnbA, fnbB, hld, hlg and hlg2. ebpS-v indicates ebpS gene with internal deletion as described previously [18].
bThe following genes were not detected in any strain: sed, see, seh, sej, sep, ser, ses, set, seu, eta, etb, etd and tst-1.
cThe following genes were undetectable in any strains: tet(L), tet(M), ermA, msrA, aph(30)-IIIa, acc(60)-Ii, acc(60)-Im, ant(9)-Ia, ant(9)-Ib, ant(300)-Ia, aph(200)-Ib, aph(200)-Ic and aph(200)-Id.










































































NMNI Aung et al. Staphylococci isolates in Myanmar 63antimicrobial agents of S. haemolyticus was observed in the pre-
sent study. Although the mecA-positive rate in S. aureus was still
low, a high rate of methicillin-resistant S. haemolyticus as well as
S. epidermidis may alert us to the potential increase of drug-
resistant isolates among staphylococcal species, including MRSA.
In the present study, the detection rate of PVL genes among
S. aureus was notably high (40%), which may be related to a high
proportion of wound swabs and pus (67%) in the specimens
examined. Detection of PVL genes in six different STs among
20 S. aureus isolates suggests dissemination of PVL phages to
multiple clones, while only the dominant clone, ST121, appears to
spread within hospitals. Strain MMR-42A is the ﬁrst PVL-positive
MRSA isolated in Myanmar, having SCCmec-IV and genetic types
ST88/spa-t729/agr-III/coa-III. The ST88MRSAwith SCCmec IV or
V has been reported in both community and hospital settings in
Africa (mostly in East Africa; Tanzania and Madagascar) [31–33]
and Asia (mostly in China) [15,34,35], and less frequently in
Europe [36–38], exhibiting agr type III and various spa types, with
t186 being dominant. The spa type t729 detected in strain MMR-
42A is genetically closely related to t186 and was described also
for ST88 MRSA isolates in Africa [38], suggesting close related-
ness to the previously described ST88 clone. PVL is associated
with a part of ST88 MRSA as well as MSSA. In Bangladesh and
China, neighbouring countries to Myanmar, PVL-positive ST88
MSSA and/or MRSA was reported [34,39,40]. Detection of ST88
MRSA in Myanmar suggests the potential spread of this clone in
Asia, and there should be concern in healthcare settings resulting
from the presence of PVL in this clone.
ST121 MSSA, mostly belonging to agr-IV, are distributed
worldwide (mainly Africa, Asia and Europe) as a common cause
of SSTI, often associated with PVL, while MRSA with this ST is
rare [41,42]. In our previous study in Myanmar on S. aureus
isolates from wound/pus, food poisoning and healthy adults
[18], PVL genes were detected in only ST121 MSSA strains with
coa-Va/agr-IV from wounds in hospitalized patients. In the
present study, ST121 was dominant among PVL-positive iso-
lates and showed genetically identical traits to those of previous
MSSA strains in Myanmar. Characteristically, ST121 S. aureus in
Myanmar has been previously revealed to harbour the genes of
bone sialoprotein and a variant of elastin binding protein with
180 bp deletion [18], which was also found in PVL-positive
ST121 MSSA in the present study. Therefore, we suggest that
a single ST121 PVL-positive S. aureus clone has been persisting
as a cause of SSTI in Myanmar. Although virulence of ST121
MSSA might be increased with PVL and other toxins, this clone
is generally susceptible to most antimicrobial agents. Thus,
active promotion of early detection and treatment is recom-
mended for infections with this clone in healthcare settings.
It is of note that a novel staphylocoagulase genotype, coa XIII,
was assigned to a PVL-positiveMSSA strain (MMR-v) belonging toNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access artithe rare ST1153, which was isolated from 55-year-old patient
with wound infection. The D1 and D2 regions of staph-
ylocoagulase which deﬁne the coa genotype (subtype) is
considered to be responsible for antibody recognition as well as
contact with prothrombin [43,44]. Accordingly, genetic diversity
of the D1/D2 regions is suggested to be caused by selection with
antibody and/or prothrombin in the host. Hence, increased
virulence is concerned with the emergence of S. aureus with the
new coa type as a result of the absence of immune response
against the novel antigen of the virulence factor. In the present
study, ST1930 MSSA was resistant to erythromycin and levo-
ﬂoxacin, which is the distinctive feature of resistance among PVL-
positive isolates. Although the signiﬁcance of ST1930MSSA is not
evident, S. aureus with CC96, to which ST1930 belongs, is
revealed to secrete variable to high levels of alpha toxin [45],
suggesting relevance to the increased virulence. Therefore, the
prevalence of the novel PVL-positive MSSA clones ST1153 and
ST1930 should be carefully monitored in Myanmar.
Despite low MRSA rates among S. aureus in the present
study, it was notable that ST59 was identiﬁed in two isolates
with SCCmec-IV as well as an MSSA isolate. These isolates were
PVL negative, however, resistant to multiple antimicrobial
agents harbouring resistance genes such as erm(B). ST59
(CC59) MRSA has been classiﬁed into some groups [3,42], with
PVL-positive strains with SCCmec-V predominating in Taiwan
and other Asian countries (Taiwan clone), SCCmec-IV-har-
bouring PVL-positive strains known as USA1000 clone mostly
restricted to the United States and PVL-negative (or positive)
MRSA with SCCmec-IV or V in Australia. The ST59 PVL-
negative MRSA-IV, with the same genetic traits as the ST59
isolates in the present study, was also detected at a high rate in
the nasal cavities of children in Taiwan [46]. Thus, we suggest
that ST59 S. aureus may be distributed widely in Asia as well as
Australia and may occasionally acquire SCCmec and/or PVL
phage, associated with their clonal spread. In Myanmar, caution
may be necessary for the ST59 MRSA in hospitals regarding
acquisition of PVL genes and more drug resistance.
In summary, the present study elucidated drug resistance and
genetic traits of clinical isolates of staphylococci in a tertiary-
care hospital in Myanmar. Further studies are needed in this
country to survey the prevalence of methicillin-resistant CNS,
MRSA and PVL-positive S. aureus and their drug resistance for
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